Cargando…

PNS173 Impact of COVID-19 on HTA Bodies and Pharmaceutical Company Pricing and Market Access Activities

Detalles Bibliográficos
Autores principales:	Thomas, M., Craddy, P., Foxon, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631951/ http://dx.doi.org/10.1016/j.jval.2020.08.1617

Ejemplares similares

Timely, consistent, transparent assessment of market access evidence: implementing tools based on the HTA Core Model® in a pharmaceutical company
por: Ducournau, Pierre, et al.
Publicado: (2019)

The Impact of Brexit on Pharmaceuticals and HTA
por: Lorgelly, Paula K
Publicado: (2018)

Pharmaceutical companies’ views on a health technology assessment (HTA) entity in Saudi Arabia
por: Al-Omar, Hussain Abdulrahman, et al.
Publicado: (2020)

The Impact of Customer Psychological Price on Audit Pricing in the Start-Up Company Market
por: Ding, Rui
Publicado: (2020)

PNS78 Impact of COVID on Health Technology Assessment bodies
por: Macaulay, R.
Publicado: (2021)

The impact of external reference pricing on pharmaceutical costs and market dynamics
por: Voehler, Dominic, et al.
Publicado: (2023)

Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies
por: Smith, Richard
Publicado: (2005)

HTA and National Immunisation Program: an overview of competent bodies and of the impact of HTA on the decision-making process
por: Ricciardi, W
Publicado: (2022)

From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries
por: Panteli, Dimitra, et al.
Publicado: (2015)

Drug repurposing in pharmaceutical industry and its impact on market access: market access implications
por: Murteira, Susana, et al.
Publicado: (2014)

Attitude and practice of dental surgeons towards pharmaceutical companies’ marketing gifts
por: Tahir, Shaila, et al.
Publicado: (2013)

Impact of COVID-19 pandemic on HTA
Publicado: (2020)

Expected Impact of Biosimilars on the Pharmaceutical Companies
por: Golshani, Shiva, et al.
Publicado: (2021)

PHARMACEUTICAL PRICING IN EMERGING MARKETS: EFFECTS OF INCOME, COMPETITION, AND PROCUREMENT
por: Danzon, Patricia M, et al.
Publicado: (2015)

Dynamics of price competition in Italian pharmaceutical off-patent market
por: Perna, Serena, et al.
Publicado: (2022)

Reputation, Stock Price, and You: Why the Market Rewards Some Companies and Punishes Others
por: Kossovsky, Nir
Publicado: (2012)

Buyouts of Indian Pharmaceutical Companies by Multinational Pharmaceutical Companies: An Issue of Concern
por: Sreedhar, D, et al.
Publicado: (2011)

Pharmaceutical innovation and access to financial markets
por: Blau, Benjamin M., et al.
Publicado: (2022)

Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review
por: Akpinar, Ilke, et al.
Publicado: (2016)

The influence of pharmaceutical companies
por: Migone, Paolo
Publicado: (2017)

New drug regulations in France: what are the impacts on market access? Part 2 – impacts on market access and impacts for the pharmaceutical industry
por: Rémuzat, Cécile, et al.
Publicado: (2013)

HTA253 Payer Perspectives on the Impact of the COVID-19 Pandemic on Health Technology Assessments (HTA) in Europe
por: Hutcheson, R, et al.
Publicado: (2022)

Use of the Certificate for Pharmaceutical Products (CPP) in 18 Maturing Pharmaceutical Markets: Comparing Agency Guidelines with Company Practice
por: Rodier, Céline, et al.
Publicado: (2020)

Challenges of access to medicine and the responsibility of pharmaceutical companies: a legal perspective
por: Ahmadiani, Saeed, et al.
Publicado: (2016)

The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders
por: Wasir, Riswandy, et al.
Publicado: (2019)

Worldwide HTA access to ICER's cost-effectiveness models
Publicado: (2020)

Doping Doctors: The Influence of the Marketing Departments of Pharmaceutical Companies on Physician and Researcher Behavior in Japan
por: Ichikawa, Iekuni, et al.
Publicado: (2016)

Public health and corporate social responsibility: exploratory study on pharmaceutical companies in an emerging market
por: Dănescu, Tatiana, et al.
Publicado: (2020)

Pharmaceutical market access in emerging markets: concepts, components, and future
por: Kumar, Anuj, et al.
Publicado: (2014)

Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
por: Badora, Karolina, et al.
Publicado: (2017)

The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors
por: von der Schulenburg, Fritz, et al.
Publicado: (2011)

Comment on: “Forecasting Pharmaceutical Prices for Economic Evaluations When There is No Market: A Review”
por: Holko, Przemysław
Publicado: (2017)

Pharmacovigilance in pharmaceutical companies: An overview
por: Mammì, Maria, et al.
Publicado: (2013)

Inequities in access to depression treatment: results of the Brazilian National Health Survey – PNS
por: Lopes, Claudia Souza, et al.
Publicado: (2016)

Market Prices
por: Beecher, Thos. K.
Publicado: (1885)

PNS263 Pandemics and Access to Care: Use of Real-World DATA to Examine the IMPACT of COVID-19 on Pharmacy Visits in JAPAN
por: LoPresti, M., et al.
Publicado: (2020)

How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory‐HTA parallel scientific advice
por: Tafuri, Giovanni, et al.
Publicado: (2016)

PRO103 The IMPACT of COVID-19 on the Future Pricing and Market Access of RARE Diseases and CELL-/GENE-Therapies
por: Teale, C., et al.
Publicado: (2020)

Drug reformulations and repositioning in the pharmaceutical industry and their impact on market access: regulatory implications
por: Murteira, Susana, et al.
Publicado: (2014)

Impact of Generic Price Linkage System and Reference Price System on prices of pharmaceuticals – comparison of Austria and Finland
por: Martikainen, Jaana E, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_osmdsfimhvedo062dpcsu074k8